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Human rhinovirus (HRV) infections up-regulate proinflammatory
mediators andgrowth factors thatareassociatedwithexacerbations
of inflammatory airway diseases, such as asthma and chronic
obstructive pulmonary disease (COPD). Matrix metalloproteinase
(MMP)-9 was shown to be increased in the airways of patients with
asthma and COPD. We sought to determine whether HRV infection
modulated the expression of MMP-9 and its highest-affinity in-
hibitor, the tissue inhibitor of metalloproteinase (TIMP)-1, and we
explored the mechanism by which this modulation occurs. In vitro
studies, usingRT-PCR, ELISA, zymography, and afluorescent activity
assay, demonstrated that MMP-9 mRNA, protein, and activity were
increased upon infection with HRV, whereas TIMP-1 mRNA and
protein remained unchanged. These results were verified in vivo,
using nasal lavage samples obtained from subjects with confirmed
rhinovirus infections. Human rhinovirus infections were shown to
up-regulateNF-kB, andNF-kB has also been reported to play a role in
theexpressionofMMP-9.Wetherefore investigated the roleofNF-kB
in HRV-induced MMP-9 expression. Using two inhibitors of IkBa
kinase b, we observed a concentration-dependent decrease in HRV-
inducedMMP-9expression. The roleofNF-kB inHRV-inducedMMP-9
expression was further confirmed using MMP-9 promoter luciferase
constructs, which demonstrated that an NF-kB site at 2620/2607
base pairs was necessary for HRV-induced MMP-9 expression. Elec-
trophoretic mobility shift assays and supershift assays confirmed the
nuclear translocation and binding of p50/p65 NF-kB subunits to an
MMP-9–specific NF-kB oligonucleotide. This increase in MMP-9 may
be a mechanism by which rhinovirus infections contribute to airway
inflammation and, potentially, to airway remodeling.
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Human rhinovirus (HRV) infections are associated with exac-
erbations of lower airway diseases, such as asthma and chronic
obstructive pulmonary disease (COPD) (1). More than 100
serotypes of HRV exist, and they may be grouped according to
the cell surface receptor used to gain entry into airway epithelial
cells, which are their primary site of infection (2, 3). More than
90% of these HRV serotypes belong to the major group that
attaches to the host cell via intercellular adhesion molecule-1,
whereas at least 10 serotypes belong to the minor group and use
members of the low-density lipoprotein receptor family for
attachment (4).
Although HRV infections are strongly linked to exacerba-
tions of asthma and COPD, the mechanisms by which such
infections cause these exacerbations are not yet fully charac-
terized. It was demonstrated that the HRV infection of airway
epithelial cells in vitro induces the production of various
cytokines, chemokines, growth factors, and host defense pro-
teins, several of which are also detected in airway secretions
during in vivo HRV infections (5, 6). According to the current
paradigm, these cellular products serve as chemoattractants and
activators for the inflammatory cells that are recruited to the
airways during disease exacerbations.
Matrix metalloproteinases (MMPs) are a family of 24 pro-
teolytic enzymes that play an important role in inflammatory
cell recruitment by contributing to the disruption of extracel-
lular matrix and cellular junctions. They can also regulate the
availability, activation, and inactivation of numerous proteins,
including growth factors, cytokines, and chemokines. Matrix
metalloproteinase-9 is the largest and most structurally com-
plex member of the MMPs (7). The high-affinity, endogenous
inhibitor of MMP-9, the tissue inhibitor of matrix metallopro-
teinase (TIMP)-1, forms a stoichiometric 1:1 complex with
MMP-9, and the balance between TIMP-1 and MMP-9 expres-
sion plays an important role in regulating MMP-9 activity within
tissues.
The expression of MMP-9 is increased in the sputum of
patients experiencing an exacerbation of COPD, and in the
lavage samples of patients experiencing asthma exacerbations
(8, 9). Given that HRV infections are causally associated with
exacerbations of COPD and asthma, we hypothesized that
HRV infection may also alter the epithelial expression of
MMP-9. Here we provide the first demonstration that HRV
infection of human bronchial epithelial (HBE) cells in vitro
increases the expression of MMP-9, but not of TIMP-1, and that
this HRV-induced production of MMP-9 occurs via an NF-kB–
dependent mechanism. We further extend these studies to
demonstrate that levels of MMP-9, but not of TIMP-1, are
increased in nasal secretions from otherwise healthy individuals
with confirmed, naturally acquired HRV infections. These
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results suggest that MMP-9 may contribute to the pathogenesis
of HRV-induced exacerbations of COPD and asthma. Part of
this work was published in abstract form (10, 11).
MATERIALS AND METHODS
Materials
Reagents were obtained from suppliers as indicated: Ham’s F-12
medium, Eagle’s minimal essential medium, Hanks’ balanced salt
solution, penicillin–streptomycin–amphotericin B, L-glutamine, TRIzol
reagent, sodium pyruvate, nonessential amino acids, gentamicin, FBS
(Invitrogen Life Technologies, Burlington, ON, Canada), bronchial
epithelial cell growth medium (BEGM; BioWhittaker, Walkersville,
MD), TaqMan master mix, 203 glyceraldehyde-3-phosphate dehydro-
genase (GAPDH), RNase inhibitor and reverse transcriptase (Applied
Biosystems, Foster City, CA), MMP-9 and TIMP-1 ELISAs (matched
antibody pairs), MMP-9 fluorogenic activity assay (R&D Systems,
Minneapolis, MN), PS-1145, ML120B (Millennium Pharmaceuticals,
Cambridge, MA), TransIT (Mirus, Madison, WI), pGL4.10[luc2]
vector (Promega, Madison, WI), Firefly luciferase assay kit (Biotium,
Inc., Hayward, CA), and antibodies used in supershift experiments for
p50 (sc-114), p65 (sc-109), c-Rel (sc-70), and p52 (sc-848) (Santa Cruz
Biotechnology, Santa Cruz, CA). All other chemicals were purchased
from Sigma-Aldrich (St. Louis, MO).
In Vitro Virus Preparation
The HRV major serotype 16 (HRV-16) and minor serotype 1A (HRV-
1A) were propagated in WI-38 fibroblasts and H1-HeLa cells (American
Type Culture Collection, Rockville, MD), respectively, and purified via
centrifugation on a sucrose cushion, as described previously (12). Viral
titers were determined using WI-38 or H1-HeLa cells grown in 96-well
plates, as described previously (13). Replication-deficient HRV-16 and
HRV-1A were produced by exposure of aliquots of the purified viral
stock to a Spectroline model XX-15F high-intensity, short-wavelength
(254 nm) ultraviolet (UV) lamp, at a distance of 5 cm for 7 minutes.
Inactivation was confirmed by the inability of stocks to replicate and
cause cytopathic effects in WI-38 or H1-HeLa cells, respectively.
Culture and Viral Infection of Bronchial Epithelial Cells
Primary human bronchial epithelial (HBE) cells were obtained by the
protease digestion of nontransplanted normal human lung tissue (14),
and the BEAS-2B cell line was a gift from Dr. Curtis Harris (National
Cancer Institute, Bethesda, MD). These cells were cultured on 6-well
culture plates (Corning, Inc., Corning, NY) in serum-free BEGM. Cells
were pretreated for 4 hours in bronchial epithelial basal media
(BEBM) before stimulation with virus, and this basal medium was
used in all experimental procedures. Subconfluent (70–80%) HBE cell
monolayers were washed with HBSS and exposed to HRV-16 or HRV-
1A. Primary cells were infected with a 105.5 50% tissue culture-
infective dose (TCID50) U/ml (multiplicity of infection [MOI], z
1.0), whereas BEAS-2B cells were infected with 104.5 TCID50 U/ml
(MOI, z 0.1). The higher dose used in primary cells is necessary to
ensure robust responses, because even at high doses of HRV, no more
than 10% of HBE cells are infected (15). Cells were incubated at 348C
for the times indicated, at which point supernatants and total cellular
RNA were harvested (using TRIzol reagent) and stored at 2808C for
later analysis. Each ‘‘n’’ represents an individual primary donor or
individual BEAS-2B passage.
Real-Time RT-PCR
The expression of MMP-9 and TIMP-1 mRNA was quantified using an
Applied Biosystems Model 7900 Sequence Detector. The treatment of
samples with DNase I (Ambion, Austin, TX) ensured minimal genomic
contamination. Input RNA (400 ng) was reverse-transcribed into
cDNA, followed by PCR amplification in the presence of specific
forward and reverse primers (University of Calgary DNA Services,
Calgary, AB, Canada) and probes (Applied Biosystems). Primers and
probe for MMP-9 included forward primer 59-GCCTTTGGACACG
CACG-39, reverse primer 59-AGCGGTCCTGGCAGAAATAG-39,
and probe (spanning the junction of exons 12 and 13) 59-FAM-
TTCCAGTACCGAGAGAAA-39. Primers and probe for TIMP-1
included forward primer 59-GACGGCCTTCTGCAATTCC-39, re-
verse primer 59-TCTGGTGTCCCCACGAACTT-39, and probe (span-
ning exons 1 and 2) 59-FAM-CCTCGTCATCAGGGC-39. Analysis of
the housekeeping gene GAPDH was performed on each sample, using
a primer and probe kit obtained from Applied Biosystems (catalogue
number 4326317E). Both MMP-9 and TIMP-1 mRNA concentrations
were calculated using the comparative CT method, as previously
described (16), and are expressed relative to GAPDH.
ELISAs and MMP-9 Fluorogenic Assay
We performed ELISA assays for MMP-9 and TIMP-1 protein, using
matched antibody pairs according to the manufacturer’s protocol
(R&D Systems, Minneapolis, MN), with recombinant MMP-9 and
TIMP-1 used as standards. The sensitivities of the assays were 23 pg/ml
for MMP-9, and 31 pg/ml for TIMP-1. The active MMP-9 fluorescence
assay was performed according to the manufacturer’s protocol (R&D
Systems), and consisted of applying cellular supernatants onto a plate
precoated with an antibody directed to human MMP-9 (both propeptide-
containing and active forms). After washing to remove unbound sub-
stances, a fluorogenic substrate molecule linked to a quencher was added.
Active MMP-9 cleaves the link between the quencher and fluorescent
molecule, resulting in a fluorescent signal. Interpolation of a standard
curve (recombinant MMP-9 activated with 4–p-aminophenyl mercuric
acetate [APMA]) allows for the quantification of MMP-9 activity.
Gelatin Zymography
The standardization of protein loaded onto each gel was performed
using a detergent-compatible protein assay (Bio-Rad, Montreal, PQ,
Canada). Nonreducing Laemmle’s buffer was added to the superna-
tants, and proteins were immediately separated on 7.5% SDS-PAGE
gels containing 1 mg/ml gelatin. After electrophoresis, gels were
washed in rinse buffer (50 mM Tris-HCl, 10 mM CaCl2, 1 M ZnCl2,
and 2.5% Triton X-100) for 15 minutes, and incubated overnight in
fresh rinse buffer. Gels were subsequently rinsed with distilled water
and incubated in reaction buffer (50 mM Tris-HCl, 10 mM CaCl2, and 1
M ZnCl2) for 24 hours at 378C. Gels were stained with Coomassie blue
R-250 (2.5 mg/ml in 30% isopropanol and 10% acetic acid) for 1 hour
and then destained in 10% isopropanol and 10% acetic acid until clear
bands were visible. The activity of MMP-9 was identified as clear bands
where the gelatin had been degraded. A Fluor-S MAX MultiImager
(Bio-Rad Laboratories, Hercules, CA) was used to capture images of
the gels. Positive controls were generated by exposing MMP-9–rich
supernatant from TNF-a (10 ng/ml)-activated neutrophils to APMA
(1 mM) at 378C for 2 to 4 hours.
Luciferase Promoter Constructs
A 1,717-base pair (bp) MMP-9 promoter construct, corresponding to
the sequence from 21723 to 26 relative to the transcription start site
of the 59-flanking region of the human MMP-9 gene, was generated
from human genomic DNA, using specifically designed forward 59-CAT
GGTACCATGCTCATGCCCGTAATCC-39 and reverse 59-CATGC
TAGCGGCAGAGGTGTCTGACTGC-39 primers incorporating Kpn1
and Nhe1 restriction sites (underlined) at the 59 ends and 39 ends,
respectively. The amplicon was then inserted upstream of the luciferase
reporter gene in the pGL4.10[luc2] vector (Promega). Putative transcrip-
tion factor-binding sites were identified using Genomatix MatInspector
program analyses and precedents from the literature (17–19). The var-
ious truncations were generated using custom-designed primers, again
incorporating the relevant restriction enzyme sites (underlined) to al-
low for proper orientation upstream of the luciferase reporter, 1,017-bp
construct forward 59-CATGGTACCTCTGGGCTCAAGCAATCC-39,
the 940-bp construct 59-CATGGTACCCCATACCTGGCCCTGAA
TCT-39, the 681-bp construct 59-CATGGTACCTGCTACTGTCCCCT
TTACTGC-39, the 604-bp construct 59-CATGGTACCTGCCTAGCA
GAGCCCATT-39, the 553-bp construct 59-CATGGTACCCTGAGT
CAAAGAAGGCTGT-39, and the 324-bp construct 59-CATGGTACC
CCCTCCCTCCCTTCATACA-39. All constructs were sequenced and
confirmed to be identical to those reported for the MMP-9 promoter on
chromosome 20. Point mutations within the various transcription
factor-binding sites were performed, using standard site-directed
mutagenesis methodologies within the 1,017-bp construct. Forward
primer sequences, with lowercase letters to indicate mutated residues,
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comprised the mutated interferon regulatory factor-4 (mIRF4), 59-
TGCTGTTgTCTAtAGGCTGCT-39; mNF-kB-1, 59-AGACAGGGtGT
TGCaCCAGT-39; mNF-kB-2, 59-GTtGAATTaCCCAGCCTTGC-39;
mNF-kB-1,2, 59-GtGTTGCaCCAGTtGAATTaCCCAGCC-39; and
mNF-kB-3, 59-GGGtGATCCaTCCAGCTTCATCC-39. All construct
sequences were confirmed using DNA sequencing.
Promoter Construct Transfection and Luciferase Assay
Each MMP-9 promoter construct (0.2 mg/ml) was transiently trans-
fected into subconfluent (30–40%) monolayers of BEAS-2B cells for 5
hours in basal medium using TransIT (Mirus). Cells were then allowed
to recover overnight in BEGM containing 5% FBS. The next day, cells
were infected with HRV-16, as already described. At 48 hours after
HRV infection, cells were lysed in luciferase lysis buffer (Promega),
followed by scraping, freezing, and centrifugation. Firefly luciferase
activity was measured using a luciferase reporter assay system. Six
separate experiments (n 5 6) were performed, and the results of each
experiment were averaged from triplicate wells.
Electrophoretic Mobility Shift Assay and Supershift Assays
Primary and BEAS-2B cells were infected with HRV as already
described. At the appropriate time, nuclear extracts were isolated, as
previously described (20). Double-stranded oligonucleotides contain-
ing the NF-kB-1,2 recognition site from the MMP-9 promoter were
labeled with T4 polynucleotide kinase (New England Biolabs, Picker-
ing, ON, Canada) and [g-32P]ATP (PerkinElmer, Boston, MA). For
binding reactions, 2.5 mg of nuclear extracts were incubated with 4 ml of
binding buffer (20% glycerol, 5 mM MgCl2, 2.5 mM EDTA, 1 mg of
poly(dI:dC), 250 mM NaCl, 50 mM Tris-HCl, and 0.01 M DTT). Buffer
D (0.02 M Hepes, pH 7.9, 20% glycerol, 0.05 M KCl, 0.2 mM EDTA,
pH 8.0, 0.5 mM PMSF, and 0.01 M DTT) was used to bring the mixture
to 14 ml. Samples were incubated for 20 min, labeled probe was added,
and samples were further incubated for 1 hour on ice. For supershift
assays, samples were incubated with the appropriate antibody for 2
hours before the addition of the labeled probe. Samples were fraction-
ated on 6% acrylamide gels, before vacuum drying and autoradiogra-
phy. The forward oligonucleotide sequence was 59-GAAGACAGG
GGGTTGCCCCAGTGGAATTCCCCAGCCTTGC-39.
Clinical Study Design and Methods
We performed a prospective, cross-sectional study in which otherwise
healthy, nonsmoking, nonallergic subjects were invited, through local
advertizing, to report to the research clinic within 36 hours after the
onset of cold symptoms. Subjects completed a validated symptom
questionnaire (16) and underwent nasal lavage, as described previously
(6). Symptom scores and nasal lavage were repeated on the 2 sub-
sequent days. After the resolution of cold symptoms, 4 weeks after the
third visit, subjects returned to the clinic for a retrospective baseline
visit (visit 4), at which time symptom scores and nasal lavage were
repeated. We also recruited healthy, nonsmoking control subjects
without cold symptoms, whose outcomes were measured during a single
visit. All subjects provided written, informed consent, and the protocol
was approved by the Conjoint Health Ethics Board of the Faculties of
Medicine, Nursing, and Kinesiology, University of Calgary.
Nasal lavage samples were centrifuged at 2,500 3 g for 5 minutes at
48C, and BSA was added to supernatants at a final concentration of
0.5%. Lavage supernatant samples were then aliquoted and stored at
2808C for later analysis. Viral RNA from nasal lavage samples was
isolated using the QIAamp Viral RNA Mini Kit (Qiagen, Mississauga,
ON, Canada), as described previously (6). The RNA was reverse-
transcribed using oligo(dT) and Superscript II (Invitrogen Life Tech-
nologies, Burlington, ON, Canada). Nasal lavage supernatants from all
study participants were screened for HRV, using a quantitative, real-
time RT-PCR technique. To enable the quantification of detected
HRV genomic material in nasal lavages, test samples were compared
against a standard curve that was analyzed in parallel in each assay, as
described previously (6). We also previously established that viral titers
quantified using RT-PCR correlate highly with values obtained using
standard cell-based viral titer assays (21). Samples were obtained from
nine subjects (mean age, 40 yr; range, 21–59 yr; 6 women) with
established HRV infections. Samples obtained from the same subjects
4 weeks later, when they had been symptom-free for more than 2
weeks, were confirmed to be negative for HRV by real-time RT-PCR.
Samples were obtained from 11 asymptomatic control subjects (mean
age, 28 yr; range, 22–52 yr; 6 women) who were confirmed to be
negative for HRV by real-time RT-PCR.
Statistical Analysis
All data were normally distributed, and the reported values are expressed
as means and standard errors of the mean (SEMs). Between-group
comparisons were made using one-way ANOVA, with Newman-Keuls
post hoc multiple-comparison testing to assess significant effects. De-
scriptive statistics were used to summarize the baseline characteristics of
study subjects in the clinical study. Correlations between continuous
variables were assessed using Pearson’s correlation coefficient. All
comparisons were two-tailed, and P , 0.05 was considered significant.
RESULTS
HRV Infection of HBE Cells Up-Regulates Production
of MMP-9 but Not TIMP-1
Initially we evaluated whether the HRV infection of HBE cells
resulted in any changes in MMP-9 or TIMP-1 expression. Time-
course studies showed that infection with intact HRV-16 and
HRV-1A virus, but not UV-treated, replication-deficient HRV-
16 or HRV-1A in primary HBE cells (Figures 1A and 1B, and
Figures E1A and E1B in the online supplement), and in the
BEAS-2B cell line (Figures E2A and E2B), resulted in a time-
dependent increase in the expression profiles of MMP-9 mRNA
and supernatant protein (P , 0.02). Furthermore, the infection
of HBE cells with varying dilutions of HRV-16 for 24 hours
indicated that this HRV-induced increase in MMP-9 protein
expression occurred in a concentration-dependent manner (P 5
0.003) (Figure E3). The MMP-9 expressed by HBE cells, as well
as that increased upon HRV infection, occurred only in the 92-
kD pro-form, as demonstrated by gelatin zymography (Figure
2). In addition, MMP-2 (pro-form, 72 kD), another gelatinase in
the MMP family, was constitutively expressed, but not increased
upon HRV infection (Figure 2), indicating that HRV selectively
increases MMP-9 but not MMP-2. The infection of primary
HBE cells with intact or UV-inactivated HRV-16 (Figures 1C
and 1D) or HRV-1A (Figures E4A and E4B) did not result in
the enhanced production of TIMP-1 mRNA or protein at any
time. However, the basal expression of TIMP-1 protein, but not
mRNA, increased with time, implying a time-dependent but
HRV-independent, posttranscriptional control of this protein.
The observation that only intact HRV-16 or HRV-1A increased
MMP-9 mRNA and protein suggests that initial receptor
signaling, as can occur upon the binding of UV-treated HRV-
16 to ICAM-1 (22, 23), is not sufficient for the observed increase
in MMP-9 expression. Viral replication appears to be essential.
Although zymography allows for the identification of various
forms of MMP-9, it does not determine the native activity of
MMP-9. Because the pro-domain containing the 92-kD form of
MMP-9 may be active (24), we performed an activity assay
(specific to MMP-9) to determine the native activity of MMP-9
in cell supernatants. The infection of HBE cells with both intact
HRV-16 and HRV-1A in vitro significantly increased the
activity of MMP-9 in cellular supernatants (n 5 7, P 5 0.02)
(Figures 3A and 3B, respectively). Therefore, infection with
HRV not only results in an increased expression of MMP-9, but
also increases its activity.
HRV-Induced MMP-9 Expression Is Dependent
on the Canonical NF-kB Pathway
Nuclear factor-kB is well-recognized for its role in the induction
of inflammatory genes, and was shown to be activated in
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response to HRV infection (25). The expression of MMP-9 was
reported to be dependent on NF-kB, as well as on other
transcription factors (26). We therefore sought to determine
whether HRV-induced MMP-9 expression was dependent on
NF-kB.
The expression of HRV-induced MMP-9 in both primary
HBE and BEAS-2B cells (Figures 4A and 4B, respectively) was
significantly decreased in a concentration-dependent manner
upon the addition of a small-molecule IkBa kinase b (IKKb)
inhibitor, PS-1145 (10–0.3 mM) (n 5 4, P , 0.02). At a concen-
tration of 10 mM, PS-1145 does not significantly inhibit the other
IKK family members, i.e., IKKa, TNF-receptor associated
factor (TRAF) family member–associated NF-kB activator
protein (TANK)-binding kinase 1, and IKKe (27), but was
shown to prevent the activation of NF-kB by preventing the
phosphorylation and degradation of IkBa (27, 28). Because of
concerns regarding the lack of specificity and potential off-
target effects when using a single pharmacologic inhibitor, we
used a second structurally unrelated IKKb inhibitor, ML120B.
The inhibitor ML120B (10 mM) (n 5 4, P , 0.05) significantly
inhibited HRV-induced MMP-9 protein expression (Figure E5),
thereby verifying the results obtained with PS-1145. Based on
these data, we concluded that the induction of MMP-9 expres-
sion by HRV is dependent on IKKb, and likely involves the
canonical NF-kB pathway.
Promoter Luciferase Constructs Further Highlight a Role for
NF-kB in HRV-Induced MMP-9 Expression
To evaluate further the various transcriptional regulators that
may play a role in HRV-induced MMP-9 expression, a series of
MMP-9 promoter constructs was generated in the luciferase
reporter plasmid, pGL4.10[luc2] vector (Figure 5). The tran-
sient transfection analysis of BEAS-2B cells revealed that the
HRV-induced reporter drive was 4.266 0.26 for the21,723/26 bp
construct. Because the constructs 21,017/26 bp, 2940/26 bp,
and 2681/26 bp all produced a similar level of inducibility in
response to HRV, we concluded that the DNA region between
Figure 1. Time-dependent expression of MMP-9 (A) and
TIMP-1 (C) mRNA (fold increase relative to control at
respective time point), and MMP-9 (ng/ml) (P , 0.02) (B)
and TIMP-1 (ng/ml) (D) protein upon HRV-16 infection of
primary HBE cells. Data represent mean 6 SEM (n 5 3–4).
Asterisk indicates significant differences (P , 0.05).
Figure 2. Zymography of supernatants of control (C ) cells, or cells
infected with HRV (V; HRV-1A or HRV-16) or UV-inactivated HRV-1A or
HRV-16 (UV ), after 48 hours. Bands at 92 kD are pro-MMP-9, and at 72
kD are pro-MMP-2. Figure is representative of n 5 3.
Figure 3. Activity of MMP-9 is increased upon HRV infection in vitro.
Active MMP-9 (ng/ml) was measured in supernatant of noninfected
control cells and in cells infected with HRV-16 (A) or HRV-1A (B). C,
control uninfected cells; V, HRV-infected cells. Data represent mean 6
SEM (n 5 7).
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21,723 and2681 bp upstream of the transcriptional start site is not
necessary for the HRV-induced MMP-9 promoter drive (Figure
5A).
Upon further truncation of the 681-bp construct (2604/
26 bp, 2553/26 bp, and 2324/26 bp), a loss of promoter drive
was evident (Figure 5A). These data suggest that key regulatory
DNA sites may lie in the interval 2681 to 2604 bp. The
literature (17–19) and our own Genomatix MatInspector pro-
gram analysis indicate that NF-kB sites situated at 2635/
2622 bp (NF-kB-1) and 2620/2607 bp (NF-kB-2) are the most
readily identifiable transcription factor–binding sites within this
region of the MMP-9 promoter. We therefore synthesized
constructs with mutations, designed to prevent NF-kB binding
to these sites, in either or both of the identified NF-kB binding
sites. Mutation of the first NF-kB site (NF-kB-1) did not result
in a significant decrease in MMP-9 promoter activity upon
infection with HRV. However, mutation of the second NF-kB
site, NF-kB-2, resulted in a significant abrogation of the HRV-
Figure 4. Dose-dependent decrease (P , 0.03)
in HRV-induced MMP-9 protein expression
(ng/ml) upon addition of IKKb inhibitor, PS-
1145 (10–0.3mM), in (A) primary HBE and
(B) BEAS-2B cells. Cells were pretreated with
PS-1145 for 1.5 h before infection with HRV-16,
as described in MATERIALS AND METHODS. Data
represent mean 6 SEM (n 5 4). Asterisks in-
dicate significant differences (P , 0.05).
Figure 5. MMP-9 promoter-luciferase constructs. (A) HRV-induced activity of various truncations of the MMP-9 promoter (Fold (Luciferase Activity)).
Data represent mean 6 SEM (n 5 7). Asterisks indicate significant inhibition (P , 0.05) compared with 21,723/26 bp construct. (B) HRV-induced
activity of various mutant MMP-9 promoter constructs (Fold (Luciferase Activity)). Data represent mean 6 SEM (n 5 7). Asterisks indicate significant
inhibition (P , 0.05) compared with 21,017/26 bp construct. Transcription factor–binding sites in MMP-9 promoter; AP-1, activator protein-1;
IRF4, interferon regulatory factor 4; NF-kB, nuclear factor-kB; STAT3, signal transducer and activator of transcription-3; Sp-1, Sp-1-binding site; Ets,
polyoma enhancer A binding protein-3.
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induced promoter drive, suggesting that the second NF-kB site
is necessary for HRV-induced MMP-9 expression. This was
similar to results obtained upon mutation of both sites
together (mNF-kB-1,2) (Figure 5B).
To confirm that the NF-kB site between2553/26 bp and2324/
26 bp (NF-kB-3) was not cooperating with NF-kB-1 and/or NF-
kB-2, it was also mutated. However, no decrease in viral drive was
observed, indicating that this proximal NF-kB site does not play a
role in HRV-induced MMP-9 expression (Figure 5B). A putative
IRF4 site at 2699/2678 bp was also identified by MatInspector
analysis. A mutation of this site, however, produced no decrease in
the HRV-induced promoter drive (Figure 5B), again suggesting
that this site is not necessary for HRV-induced MMP-9
expression. Other investigators reported on the importance of
either one of these two NF-kB sites within this area of the
human MMP-9 promoter (17, 29–31), and based on our data,
the NF-kB-2 site is evidently necessary for HRV-induced
MMP-9 expression.
Electrophoretic Mobility Shift Assay Analysis of NF-kB
Nuclear Localization and DNA Binding
To confirm NF-kB nuclear localization and DNA binding, we
performed an electrophoretic mobility shift assay (EMSA) and
supershift assays. Using a radiolabeled oligonucleotide probe
containing the sequence of NF-kB-1,2 and nuclear extracts
obtained from uninfected or HRV-infected primary HBE and
BEAS-2B cells, we initially performed time-course studies with
EMSA that revealed increased binding upon infection with
HRV. Binding peaked at 9–24 h after infection in primary cells,
and at 6 to 24 hours after infection in BEAS-2B cells (Figures
6A and E6, respectively). Two specific complexes were evident
in each case. To explore the composition of these two DNA-
binding complexes, supershift analysis was performed, using
a panel of commercially available antibodies. Supershift anal-
ysis revealed a shift in bands 1 and 2 with an antibody to p50,
and a shift of band 1 using an antibody to p65, suggesting that
band 1 may comprise p50/p65 heterodimers, whereas band 2
may represent p50 homodimers. Using an antibody to c-Rel, we
noted the appearance of a low-intensity complex that migrated
between the upper NF-kB complex and the top of the gel.
However, because a corresponding reduction did not appear to
occur in either of the two main NF-kB bands, we concluded that
c-Rel can only represent a minor component of these DNA-
binding complexes (Figure 6B).
HRV Infection In Vivo Is Associated with Increased MMP-9
Protein and Activity, but No Change in TIMP-1 Protein
To verify our in vitro data, we performed an in vivo natural cold
study. Protein concentrations of MMP-9 and TIMP-1 were
assessed in nasal lavage fluids from nine subjects with confirmed
rhinovirus infections during the 3 days of cold symptoms, and
during a 4-week retrospective baseline visit. Concentrations of
MMP-9 were significantly higher during HRV infection than at
baseline after clearance of the HRV infection (P 5 0.007). In
addition, the amount of MMP-9 in the lavage samples during
the baseline visit was not statistically different from the amount
in noninfected control subjects. Concentrations of MMP-9 also
correlated with viral titers (r 5 0.976 and P 5 0.005), indicating
that HRV infection upregulates MMP-9 protein concentrations
in nasal lavage samples of infected individuals (Figure 7A).
However, the expression of TIMP-1 remained unchanged, at
concentrations similar to those observed in asymptomatic
control subjects throughout visits 1–4 (Figure 7B). In addition,
the MMP-9 activity measured in nasal lavage samples, obtained
during the highest viral titer visit, was increased significantly
compared with the activity during the retrospective baseline
visit (n 5 9, P 5 0.01). Consistent with the observation that
MMP-9 protein concentrations in the lavage sample during the
baseline visit were similar to those in uninfected control sub-
jects, the amount of active MMP-9 present during the baseline
visit did not differ from that in lavage samples from uninfected
control subjects (n 5 11) (Figure 7C).
DISCUSSION
We provide the first demonstration that in vitro infection with
major or minor HRV serotypes selectively up-regulates the
airway epithelial cell production of MMP-9 mRNA, protein,
and activity, without affecting concentrations of the highest-
affinity inhibitor of MMP-9, TIMP-1. A similar result was
obtained upon the HRV-16 infection of nasal polyp fibroblasts,
when an increase in MMP-9 but not TIMP-1 expression was
evident (32). Our in vivo results confirm our in vitro observa-
tions. Nasal lavage samples obtained from individuals with
confirmed HRV infections demonstrated increased MMP-9
protein concentrations and activity, which subsequently de-
creased as viral titers declined. Concentrations of MMP-9
protein were highest at the time of peak viral titer, and declined
Figure 6. HRV-induced NF-kB nuclear transloca-
tion and DNA binding. (A) HRV infection of primary
HBE cells induces two bands (band 1 and 2) during
incubation of nuclear extracts, obtained at indi-
cated time points (1–48 h after infection), with
g-32P-labeled NF-kB-1,2 oligonucleotide. (B )
Supershift experiments reveal p65/p50 hetero-
dimer (band 1) and p50/p50 homodimer (band
2). C, control uninfected cells; V, HRV-infected
cells; NS, nonspecific. Figure is representative of
n 5 3.
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to concentrations similar to those in healthy, noninfected
control subjects after confirmed clearance of the HRV in-
fection. In contrast, concentrations of TIMP-1 were not signif-
icantly affected and remained relatively constant during acute
infection and during the retrospective baseline visit.
In our studies using cultured HBEs, zymography indicated
that only the 92-kD form of MMP-9 was present. To display
activity while retaining its pro-domain, disruption of the active
site zinc–thiol interaction of MMP-9 would have to occur via
nonproteolytic means (33). We speculate that alterations in the
MMP-9/TIMP-1 molar ratio, attributable to the selective in-
crease in MMP-9 relative to TIMP-1, contribute to the increase
in MMP-9 activity. This active MMP-9 may facilitate cellular
recruitment via disruption of the extracellular matrix and cell
junctions, and could modulate the activity of numerous cyto-
kines, chemokines, and growth factors, resulting in altered
inflammatory profiles and cellular infiltration. However, the
exact role of MMP-9 in the immunopathology of airway in-
flammation has not been fully characterized. Murine models of
allergic airway inflammation, using MMP-92/2 mice or various
MMP inhibitors, provided varying results regarding the in-
volvement of MMP-9 in the development and resolution of
airway inflammation. Such discrepancies may, at least in part,
be attributed to different sensitization procedures and different
genetic backgrounds of the mice (34–37). A study examining the
role of MMP-9 in experimental colitis reported that epithelial
cell-derived, rather than inflammatory cell-derived, MMP-9 was
responsible for the tissue damage and inflammation in mice
exposed to dextran-sodium sulfate or infected with Salmonella
typhimurium (38).
In clinical studies, MMP-9 was shown to be increased in the
airways during exacerbations in both patients with COPD and
patients with asthma (8, 9). This increase in MMP-9 during
these clinical exacerbations is thought to play an important role
in the pathogenesis of airway inflammation, and may contribute
to altered injury-repair cycles and to airway-remodeling pro-
cesses. In support of this potential role for MMP-9 in the
pathogenesis of airway remodeling, abnormalities in high-
resolution computed tomography scans were associated with
alterations of the MMP-9/TIMP-1 ratio in patients with asthma
and COPD (39). In addition, a recent in vitro study indicated a
role for epithelial-derived MMP-9 in smooth muscle proliferation
Figure 7. MMP-9 (A) or TIMP-1 (B) protein (ng/ml) and
corresponding viral titers (TCID50/ml) in nasal lavage
samples from HRV-infected individuals at time of cold
symptoms (Days 1–3) and after clearance of viral infection
(day 28), or in noninfected control individuals (Normal).
Data represent mean 6 SEM (n 5 9 for infected in-
dividuals, n 5 11 for control subjects). (C) Active MMP-9
(ng/ml) in nasal lavage samples obtained during visit with
highest viral titer (designated visit 1), during visit 4
(retrospective baseline at day 28), and in noninfected
control subjects (Normal). Data represent mean 6 SEM
(n 5 9 for infected individuals, n 5 11 for control subjects).
Asterisks indicate significant differences (P , 0.05).
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(40). Therefore, the increase of MMP-9 protein and activity
upon HRV infection is likely to modulate both airway in-
flammation and airway-remodeling processes.
Using small-molecule IKKb inhibitors, promoter constructs,
EMSA, and supershift assays, we established that the canonical
NF-kB pathway plays an essential role in HRV-induced MMP-9
expression. This finding is consistent with earlier reports of NF-
kB–dependent MMP-9 expression in response to other stimuli
(26). The use of MMP inhibitors in animal models of allergic
airway inflammation showed promising results in reducing
airway inflammation. By contrast, the use of a broad-spectrum
MMP inhibitor in human studies resulted in numerous adverse
effects and limited clinical efficacy (41). New approaches, in
which individual MMPs specific to the disease or inflammatory
condition in question are targeted, offer a way to provide
targeted therapy with highly selective inhibitors. Our results
indicate that IKKb inhibition (during HRV-induced exacerba-
tions) selectively inhibited the increase in MMP-9 expression,
thereby maintaining the MMP-9/TIMP-1 ratio at a steady-state
level.
Our study has several limitations. The MMP-9 measured in
nasal lavage samples did not distinguish between protein
generated by airway epithelial cells, and that generated by
granulocytes. Neutrophils are a major source of MMP-9 within
the airways, and MMP-9 concentrations in airways were found
to correlate with neutrophil numbers (42). Infections with HRV
are associated with increased neutrophil influx to the airways,
and so neutrophils also likely contribute to MMP-9 concentra-
tions in airway secretions. Nonetheless, epithelial cells are the
principal site of HRV infection and replication within the
airways, and our in vitro data demonstrate that the induction
of epithelial MMP-9 is dependent on HRV replication. The
strong correlation between MMP-9 concentrations and viral
titers in vivo is therefore consistent with a role for epithelial
cells as a contributor to MMP-9 concentrations.
In our in vitro experiments, we used both major (HRV-16)
and minor (HRV-1A) serotypes, and confirmed that the in-
fection of HBE cells with HRV-1A led to an approximately 10-
fold greater increase in MMP-9 protein production compared
with infection with HRV-16. The reason for this finding is not
clear, although the relative expression of the respective cell-
surface receptors used by these viruses to gain entry into
epithelial cells, and thus the percentage of cells infected, may
involve one plausible explanation for the observed differences
in MMP-9 expression. Moreover, these two virus serotypes are
titered in different cell types, and thus the TCID50 used to infect
the HBE cells cannot be compared. However, our results do
confirm that the increase in MMP-9 expression after infection
with both HRV serotypes was dependent on viral replication,
because UV-inactivated, replication-deficient HRV did not lead
to an increase in MMP-9 mRNA or protein concentrations,
compared with uninfected control cells. The role of the NF-kB
pathway in HRV-induced MMP-9 expression was demonstrated
using pharmacologic IKKb inhibitors. However, we acknowl-
edge the limitations of pharmacologic inhibitors with respect to
their specificity and possible off-target effects. To verify the
specificity of the inhibitors and our results, we used two
structurally different, well-studied IKKb inhibitors (27).
In conclusion, we have provided robust, novel evidence that
the HRV infection of airway epithelial cells significantly and
selectively upregulates MMP-9 mRNA and protein concentra-
tions through a mechanism dependent on NF-kB, but does not
affect TIMP-1 mRNA or protein concentrations.
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